What Laboratorios Bernabo does

Laboratorios Bernabó is an Argentine pharmaceutical laboratory founded in 1934 and headquartered in Buenos Aires, operating with 501–1,000 employees and 100% nationally sourced capital. The company develops, manufactures, and markets specialty medications across six therapeutic business units: Cardiometabolism, Odontology, General Medicine, Gastroenterology, Women's Health, and Skin Care (PerPiel). It is the pioneer of branded dental specialty products in Argentina, having created the Odonto Bernabó line in 1968, and maintains a broad multi-brand portfolio (Arteriosan, Alidase, Miopropan, Kala, Qura, Subical, Emgliber, Fluordent, Plac-out, Sensident, among others) with deep SKU coverage.

The underlying technology base is pharmaceutical formulation and manufacturing executed across two production facilities — Planta Terrada in Buenos Aires and Planta SB in Tortuguitas — supported by integrated internal departments for Quality Control, Quality Assurance, Experimental and Clinical Pharmacology, and Microbiology. Operations are conducted under ANMAT regulatory oversight, with prescription and OTC products distributed through a nationwide delegation network and pharmacy channels, including social security reimbursement through PAMI and IOMA. Recent R&D output is evidenced by 2024–2025 launches of Emgliber and Emgliber MET (SGLT2 inhibitor franchise for cardio-reno-metabolic care), signaling investment in modern chronic-disease therapeutics.

The business model is sales-led B2B/B2C pharmaceutical distribution: the company generates revenue from one-time product sales of branded specialty and branded generic medications to pharmacies and healthcare professionals, with no disclosed subscription, licensing, or service revenue. Marketing operates through a multi-channel approach combining a corporate website, brand-specific product websites, healthcare professional portals, social media (notably LinkedIn), and educational programs such as the Becas Bernabó scholarship for dental students. No external funding rounds, parent company, or investor involvement are disclosed.

Name

Laboratorios Bernabo

Legal name

Laboratorios Bernabó

Website

https://laboratoriosbernabo.com

Company type

Private

Founded year

1934

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Laboratorios Bernabó is a Buenos Aires–based, 100% Argentine-capital pharmaceutical laboratory founded in 1934, developing and manufacturing specialty medications across cardiometabolism, odontology, gastroenterology, women's health, dermatology, and general medicine, distributed nationwide through a delegation and pharmacy network.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

akta.pro secondary industries

Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI), Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG)

Keywords

• Pharmaceutical manufacturing
• Specialty medications
• Dental pharmaceuticals
• Cardiovascular drugs
• Dermatological products

Headquarters

HQ city

Buenos Aires

HQ country

Argentina

HQ region

Latin America

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Revenue generated from the manufacture and sale of branded generic and specialty pharmaceutical products across therapeutic categories including cardiovascular, anti-inflammatory, antibiotic, dermatological, and dental medications. Products sold through pharmacy networks and directly to healthcare professionals.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Laboratorios Bernabó develops, manufactures, and commercializes a diversified portfolio of branded specialty pharmaceutical products in Argentina, organized across six therapeutic lines: Cardiometabolismo (cardiovascular and antidiabetic), Medicina General (analgesics, anti-inflammatories, antibiotics), Gastroenterología, Odontología (its pioneer Odonto Bernabó line), Cuidado Femenino (women's health), and Cuidado de la Piel (dermatology / PerPiel line). The company produces both prescription and OTC medications, sold to healthcare professionals and to patients through its nationwide delegation network and pharmacy channels, including coverage under social security systems such as PAMI and IOMA.

Product overview

Laboratorios Bernabó is a 100% Argentinian pharmaceutical laboratory with over 90 years of experience, offering a broad portfolio of specialty medications. The company operates across five main product lines: Cardiometabolism (including Arteriosan, Qura, Emgliber), Skin Care (PerPiel dermatological line), Women's Health (Kala contraceptives, Ovufem), Gastroenterology (Miopropan, Gastec), and Odontology/Dental Care (Plac-out, Fluordent, Sensident, Dentilac). The company also offers general medicine products, pediatric formulations, and operates the Odonto Bernabó specialized dental division. Their products span therapeutic areas including cardiovascular, anti-inflammatory, respiratory, dermatological, and dental care, with medications available by prescription and over-the-counter.

Differentiator

Problem solved

Functional benefit

Brands

• PerPiel: Dermatological skincare emulsions with Vitamin A and innovative active ingredients for skin care, moisturization, and regeneration.
• Odonto Bernabó
• Becas Bernabó

Products and services

• Arteriosan
• Alidase
• Miopropan (line)
• Kala (and Kala MD)
• Qura line (Qura, Qura Grip, Qura Muk, Qura Tos, Qura Plus)
• PerPiel dermatological line
• Subical (calcium supplement line)
• Plac-out (oral hygiene line)
• Fluordent (oral care line)
• EMGLIBER
• EMGLIBER MET
• Dentilac
• Sensident
• Vasexten / Vasexten-D
• Vorst / Vorst 36 / Vorst-M

Segments6 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Roemmers: One of Argentina's largest privately-held pharmaceutical laboratories with a broad specialty-medicine portfolio across multiple therapeutic areas and nationwide pharmacy distribution — a direct Argentine peer in scale, model, and therapeutic breadth.
• Laboratorios Bagó: Argentine pharmaceutical laboratory with diversified branded specialty portfolio, manufacturing, and national distribution across cardiovascular, central nervous system, and other therapeutic areas — a direct peer in geography, business model, and category mix.
• Gador: Argentina-based pharmaceutical company producing branded specialty medications with national distribution and a presence in cardiology, gastroenterology, and other therapeutic areas — directly comparable in size, model, and therapeutic focus.
• Elea Pharma: Argentine pharmaceutical laboratory with a broad specialty-medicine portfolio and national pharmacy distribution — directly comparable as a domestic, multi-therapeutic pharma peer with branded products.
• Laboratorios Montpellier: Argentina-based pharmaceutical manufacturer with a diversified branded specialty portfolio across multiple therapeutic areas — a direct domestic peer in scale and product mix.

Broad incumbents

• Bayer (Argentina Pharma): Multinational pharmaceutical company with a strong Argentine presence in cardiovascular and women's health; competes broadly with Bernabó in cardiology and OTC pharmacy channels, though as part of a global portfolio rather than a domestic specialist.
• Roche (Argentina): Global pharmaceutical leader with significant Argentine operations across multiple therapeutic areas, including cardiology; a broader incumbent that competes for the same prescribers and pharmacy shelf space as Bernabó.
• Boehringer Ingelheim (Argentina): Multinational originator of Empagliflozin (Jardiance), the molecule in Bernabó's newly launched Emgliber franchise; a relevant incumbent in the cardiometabolic category where Bernabó is now competing.
• Sandoz: Global leader in generic and specialty pharmaceuticals with presence in Argentina; a broader incumbent that competes on price and portfolio breadth in many of the same therapeutic categories as Bernabó.

Regional players

• Laboratorio Andrómaco: Latin American pharmaceutical company with strong presence in dermatology, gynecology, and OTC categories; comparable as a regional multi-therapeutic branded pharma peer with overlapping product lines such as women's health and skin care.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/laboratorios-bernabo-s-a-

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Laboratorios Bernabo